跳至主要内容
临床试验/NCT02812888
NCT02812888Unknown不适用

Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism

Hu Hao1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
240
试验地点
1
主要终点
Serum betatrophin levels

研究概览

简要总结

Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components.

Recent evidence from HepG2 cells indicates that betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, a secreted protein that regulates glucose, lipid metabolism, and energy homeostasis, is induced by T3. However, the role of betatrophin in hyperthyroid patients is unknown.

The objective was to study serum betatrophin levels in hyperthyroid patients and the association of serum betatrophin levels with hyperthyroidism.

详细描述

Thyroid hormone (TH) is a critical hormone responsible for growth, development, and metabolism. It maintains basal metabolic rate (BMR), improves adaptive thermogenesis, and thus modulates body weight by fine-tuning energy expenditure and intake. Hyperthyroidism, a condition with excess TH, presents a status of negative energy balance that is characterized by weight loss, increased energy expenditure, and accelerated lipolysis and gluconeogenesis. The mechanism underlying hypermetabolic status in hyperthyroidism is complicated. In hyperthyroidism, excess TH promotes the metabolism rate primarily by binding to TH receptor α or β, and in turn by further influencing diverse metabolic pathways. Recent studies have revealed that TH signals were involved in cross talk with a range of other metabolic signaling pathways in different metabolic organs. In liver, TH interacts with peroxisome proliferator-activated receptor (PPAR) α, PPARγ, and liver X receptor α pathway; promotes fatty acid oxidation; decreases cholesterol; and enhances gluconeogenesis. The elements required for TH action are well documented, but understanding the interaction between TH and various pathways remains a challenge.

Betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, is a novel protein predominantly expressed in human liver. Increasing evidence has revealed associations between betatrophin expression, glycemia and serum lipid profiles, particularly in patients with obesity or diabetes. Stimulators of betatrophin, such as insulin, thyroid hormone, irisin, SIRT1 and caloric intake, are usually relevant to energy expenditure or thermogenesis. A previous report revealed that betatrophin mRNA is induced by the thyroid hormone in HepG2 cells. Subsequent studies confirmed that transcriptional regulation is dependent on the thyroid hormone receptor that binds to the betatrophin upstream element. Therefore, betatrophin is a novel gene dramatically activated by the thyroid hormone. However, there is no evidence to date showing that TH is capable of regulating betatrophin expression in human beings. The current study investigated the change of betatrophin levels in patients with hyperthyroidism before and after thionamide treatment and explored the association of serum betatrophin levels with hyperthyroidism.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of hyperthyroidism
  • Must be drug-naive before recruitment

排除标准

  • hypertension
  • pregnancy
  • lactation
  • subacute thyroiditis
  • postpartum thyroiditis
  • abnormal liver function
  • abnormal kidney function
  • infectious diseases

研究组 & 干预措施

Hyperthyroid Patients

Patients with hyperthyroidism

干预措施: thionamide treatment for 3 months (Drug)

结局指标

主要结局

Serum betatrophin levels

时间窗: Change from baseline at 3 months

次要结局

  • blood lipid profile(At baseline and at the end of the third month)
  • liver function index(At baseline and at the end of the third month)
  • hypersensitive c-reactive protein (hs-CRP)(At baseline and at the end of the third month)
  • Blood glucose(At baseline and at the end of the third month)
  • Serum insulin levels(At baseline and at the end of the third month)
  • Thyroid function index(At baseline and at the end of the third month)

研究者

发起方
Hu Hao
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Hu Hao

Deputy Director, Department of endocrinology, Principal Investigator, Clinical Associate Professor

The First People's Hospital of Xuzhou

研究点 (1)

Loading locations...

相似试验